

Francesc Bosch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2031739/publications.pdf>

Version: 2024-02-01

225
papers

11,051
citations

53939

47
h-index

37326

100
g-index

229
all docs

229
docs citations

229
times ranked

10628
citing authors

#	ARTICLE	IF	CITATIONS
1	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2022, 107, 593-603.	1.7	18
2	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
3	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2022, 6, 774-784.	2.5	42
4	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
5	Neurotoxicity-associated sinus bradycardia after chimeric antigen receptor T-cell therapy. <i>Hematological Oncology</i> , 2022, , .	0.8	2
6	Variant t(11;22)(q13;q11.2) with <i>IGL</i> involvement in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1746-1749.	0.6	1
7	Constitutive Activation of p62/Sequestosome-1-Mediated Proteophagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma. <i>Cancers</i> , 2022, 14, 923.	1.7	5
8	Abstract 3795: Early seeding of Richter transformation in chronic lymphocytic leukemia. <i>Cancer Research</i> , 2022, 82, 3795-3795.	0.4	0
9	Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. <i>Haematologica</i> , 2021, 106, 513-521.	1.7	75
10	Analysis of Cell Subsets in Donor Lymphocyte Infusions from HLA Identical Sibling Donors after Allogeneic Hematopoietic Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 53.e1-53.e8.	0.6	3
11	Reduced expansion of CD94/NKG2C ⁺ NK cells in chronic lymphocytic leukemia and CLL-like monoclonal B-cell lymphocytosis is not related to increased human cytomegalovirus seronegativity or <i>NKG2C</i> deletions. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1032-1040.	0.7	6
12	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021, 193, 325-338.	1.2	6
13	Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia. <i>Experimental Hematology</i> , 2021, 95, 68-80.	0.2	6
14	Is acute lymphoblastic leukemia with mature B-cell phenotype and <i>KMT2A</i> rearrangements a new entity? A systematic review and meta-analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 2202-2210.	0.6	2
15	Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center. <i>Leukemia and Lymphoma</i> , 2021, 62, 2288-2291.	0.6	1
16	Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia. <i>Biomarker Research</i> , 2021, 9, 37.	2.8	5
17	Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF- κ B blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation. <i>Haematologica</i> , 2021, 106, 2749-2753.	1.7	3
18	Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy. <i>Annals of Hematology</i> , 2021, 100, 2303-2310.	0.8	32

#	ARTICLE	IF	CITATIONS
19	Genetics of Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 259-265.	1.0	1
20	Combination of novel molecular targeted agent plus R-CHOP-based regimen versus R-CHOP alone in previously untreated diffuse large B-cell lymphoma (DLBCL) patients: a systematic review and meta-analysis.. <i>Annals of Hematology</i> , 2021, 100, 2969-2978.	0.8	3
21	Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6591-6601.	3.2	8
22	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <i>Annals of Hematology</i> , 2021, 100, 825-830.	0.8	2
23	Epidemiological Characterization and Determination of TP53 and IGHV Mutational Status of a Large Series of Previously-Untreated Chronic Lymphocytic Leukemia (CLL) Patients in Spain: The Epicll Study. <i>Blood</i> , 2021, 138, 1564-1564.	0.6	0
24	Early Relapse after First Line Has a Significant Impact on Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2021, 138, 1357-1357.	0.6	1
25	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020, 34, 441-450.	3.3	8
26	First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 4260-4273.	0.8	59
27	Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. <i>Journal of Neuro-Oncology</i> , 2020, 149, 13-25.	1.4	11
28	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	0.6	1
29	Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country. <i>Experimental Hematology and Oncology</i> , 2020, 9, 37.	2.0	9
30	Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy. <i>Leukemia</i> , 2020, 34, 3420-3425.	3.3	22
31	Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). <i>British Journal of Haematology</i> , 2020, 190, 854-863.	1.2	36
32	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 3546-3556.	3.2	13
33	Venetoclax-obinutuzumab: harnessing complexity. <i>Blood</i> , 2020, 135, 788-789.	0.6	0
34	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 548-555.e4.	0.2	10
35	Prognostic Impact of Metabolic Tumor Burden in Large B-Cell Lymphoma Patients Receiving CAR T-Cell Therapy. <i>Blood</i> , 2020, 136, 27-29.	0.6	0
36	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain. <i>Blood</i> , 2020, 136, 30-31.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). <i>Blood</i> , 2020, 136, 14-16.	0.6	1
38	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
39	Excellent Clinical and Pharmacokinetic Real-World Experience after Switching to Rurioctocog ALFA Pegol. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
40	Repurposing dasatinib for diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16981-16986.	3.3	21
41	Chronic lymphocytic leukaemia: from genetics to treatment. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 684-701.	12.5	154
42	Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S247.	0.2	0
43	Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory (R/R) CLL/SLL in the DUO Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S273-S274.	0.2	1
44	Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 165-178.	0.6	21
45	Acquired von Willebrand syndrome in a patient with small lymphocytic lymphoma and Sjögren's syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 239-242.	0.5	2
46	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , 2019, 6, e67-e78.	2.2	146
47	Donor lymphocyte infusion for BK virus hemorrhagic cystitis and nephropathy: a case report. <i>Bone Marrow Transplantation</i> , 2019, 54, 772-774.	1.3	4
48	Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1522-1527.	0.6	2
49	Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy. <i>Blood</i> , 2019, 134, 3035-3035.	0.6	1
50	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	0.6	152
51	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq1 1 0.784314 rgBT /Dv 4728-4728.	0.6	3
52	Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC). <i>Blood</i> , 2019, 134, 4296-4296.	0.6	2
53	Venetoclax after idelalisib: relevant progress for CLL. <i>Blood</i> , 2018, 131, 1632-1633.	0.6	5
54	Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL. <i>Oncolimmunology</i> , 2018, 7, e1432328.	2.1	20

#	ARTICLE	IF	CITATIONS
55	Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement. <i>Haematologica</i> , 2018, 103, e92-e93.	1.7	18
56	Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. <i>British Journal of Haematology</i> , 2018, 180, 666-679.	1.2	51
57	Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis. <i>Future Oncology</i> , 2018, 14, 2265-2277.	1.1	12
58	Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes. <i>Annals of Hematology</i> , 2018, 97, 1349-1356.	0.8	34
59	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 633-642.	0.6	8
60	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018, 103, 1889-1898.	1.7	19
61	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018, 32, 1778-1786.	3.3	28
62	Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series. <i>Annals of Hematology</i> , 2018, 97, 2417-2424.	0.8	8
63	Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab. <i>Blood</i> , 2018, 132, 3402-3402.	0.6	1
64	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide. <i>Journal of Clinical Oncology</i> , 2018, 36, 7531-7531.	0.8	0
65	Abstract 4568: Reversal of immune tolerance and increased anti tumoral immune response in a mouse model of CNS B cell lymphoma after combined XPO1 and BCR inhibition. , 2018, , .		0
66	Early Normalization of Serum Free Light Chain (FLC) Assays Correlates with Profound and Prolonged Responses in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 1897-1897.	0.6	0
67	Actualizaci3n de las gu3as nacionales de consenso del Grupo Espa3ol de Leucemia Linfoc3tica Cr3nica para el tratamiento y seguimiento de la leucemia linfoc3tica cr3nica. <i>Medicina Cl3nica</i> , 2017, 148, 381.e1-381.e9.	0.3	2
68	Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. <i>Experimental Hematology</i> , 2017, 48, 1-11.	0.2	54
69	Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2017, 7, 12262.	1.6	26
70	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. <i>Lancet Haematology</i> , the, 2017, 4, e475-e486.	2.2	45
71	Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM</i> FISH deletions. <i>Oncotarget</i> , 2017, 8, 54297-54303.	0.8	44
72	Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2017, 8, 742-756.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i> aberrations. <i>Oncotarget</i> , 2016, 7, 80916-80924.	0.8	29
74	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016, 34, 84-92.	0.8	26
75	A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. <i>Advances in Therapy</i> , 2016, 33, 1814-1830.	1.3	10
76	Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 544-547.	1.0	7
77	A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. <i>Leukemia</i> , 2016, 30, 929-936.	3.3	200
78	Acute Ischemic Events in Patient Receiving Direct Oral Anticoagulants for Atrial Fibrillation: Incidence, Outcome and Clinical Profile. <i>Blood</i> , 2016, 128, 1442-1442.	0.6	1
79	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). <i>Blood</i> , 2016, 128, 229-229.	0.6	12
80	Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study. <i>Blood</i> , 2016, 128, 4060-4060.	0.6	34
81	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	0.6	1
82	Pathology Results of Tissue Biopsy during Idelalisib-Associated Diarrhea/Colitis. <i>Blood</i> , 2016, 128, 4391-4391.	0.6	4
83	XPO1 Inhibition By Selinexor Synergizes with BCR Inhibition, Blocks Tumor Growth and Prolongs Survival in a Bioluminescent Animal Model of Primary Central Nervous System Lymphoma. <i>Blood</i> , 2016, 128, 463-463.	0.6	4
84	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016, 128, 624-624.	0.6	8
85	Are Direct Oral Anticoagulants Plasma Concentrations Associated with the Risk of Postoperative Bleeding? Results from the Real Life Cohort. <i>Blood</i> , 2016, 128, 3819-3819.	0.6	1
86	A Spin-Off in Non Valvular Atrial Fibrillation (NVAf) and Cancer : Doacs As a Safe and Effective Alternative to the Convencional Avks. <i>Blood</i> , 2016, 128, 5021-5021.	0.6	0
87	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. <i>Blood</i> , 2016, 128, 5589-5589.	0.6	0
88	Ibrutinib in CLL: 2 sides of the same coin. <i>Blood</i> , 2015, 126, 2173-2174.	0.6	2
89	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0143073.	1.1	24
90	Updated Survival Analysis from the CLL11 Study: Obinutuzumab Versus Rituximab in Chemoimmunotherapy-Treated Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 1733-1733.	0.6	25

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. <i>Blood</i> , 2015, 126, 493-493.	0.6	12
92	Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. <i>Oncotarget</i> , 2015, 6, 7632-7643.	0.8	41
93	Analysis of the IGHV region in Burkitt's lymphomas supports a germinal center origin and a role for superantigens in lymphomagenesis. <i>Leukemia Research</i> , 2014, 38, 509-515.	0.4	13
94	Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. <i>Leukemia</i> , 2014, 28, 1993-2004.	3.3	20
95	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
96	Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 3345-3345.	0.6	14
97	Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study. <i>Blood</i> , 2014, 124, 4675-4675.	0.6	1
98	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). <i>Blood</i> , 2014, 124, 4699-4699.	0.6	2
99	Effect of syk inhibition by TAK659 on proliferative, survival, and migratory signals from the microenvironment in chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 7058-7058.	0.8	1
100	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. <i>Blood</i> , 2014, 124, 1976-1976.	0.6	2
101	Microrna Mir-21 Is Upregulated after Different Microenvironmental Stimuli and Controls Proliferation, Chemotaxis and Chemoresistance in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 1971-1971.	0.6	0
102	Syk Inhibition By TAK-659 Overcomes Proliferative, Survival and Migratory Signals from the Microenvironment in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 4698-4698.	0.6	0
103	Ocular Adnexal Marginal Zone Lymphomas (OAMZL): Lack of Evidence for Chlamydia Psittaci (C.) Tj ETQq1 1 0.784314 rgBT 0 Overlook	0.6	0
104	Evaluation of Transjugular Liver Biopsy in the Diagnosis of Early Hepatic Dysfunction After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S283-S284.	2.0	0
105	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013, 27, 1100-1106.	3.3	167
106	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 3951-3959.	0.6	55
107	Primary gastrointestinal aspergillosis 6 months after allogeneic hematopoietic cell transplantation: a case report. <i>Transplant Infectious Disease</i> , 2013, 15, E107-10.	0.7	2
108	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. <i>British Journal of Haematology</i> , 2013, 163, 47-54.	1.2	13

#	ARTICLE	IF	CITATIONS
109	ZAP-70 Promotes the Infiltration of Malignant B-Lymphocytes into the Bone Marrow by Enhancing Signaling and Migration after CXCR4 Stimulation. PLoS ONE, 2013, 8, e81221.	1.1	15
110	Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. Blood, 2013, 122, 1793-1793.	0.6	1
111	Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 417-423.	0.6	56
112	Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research, 2012, 18, 5924-5933.	3.2	5
113	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nature Medicine, 2012, 18, 221-223.	15.2	434
114	Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma. Blood, 2012, 120, 1627-1627.	0.6	1
115	Abstract 1344: ZAP-70 enhances migration of malignant B lymphocytes toward lymphoid organs in a Burkitt lymphoma xenograft model. , 2012, , .		0
116	YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection. Blood, 2012, 120, 3868-3868.	0.6	0
117	ZAP-70 Enhances Infiltration of Malignant B Lymphocytes Into the Bone Marrow by Increasing Migratory and Survival Responses to CXCR4 Stimulation. Blood, 2012, 120, 1779-1779.	0.6	0
118	Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy. Blood, 2012, 120, 3930-3930.	0.6	0
119	5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC). Clinical Lymphoma, Myeloma and Leukemia. 2011, 11, S270-S272.	0.2	1
120	ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood, 2011, 118, 4401-4410.	0.6	48
121	Personalizing treatment for chronic lymphocytic leukemia. Expert Review of Hematology, 2011, 4, 27-35.	1.0	8
122	Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC). Blood, 2011, 118, 293-293.	0.6	1
123	Study of Causes of Death in Patients with Myelodysplastic Syndrome: A Single Institution Experience. Blood, 2011, 118, 5026-5026.	0.6	5
124	ZAP-70 Enhances Migration of Malignant B Cells towards Lymphoid Organs in a Burkitt Lymphoma Xenograft Model. Blood, 2011, 118, 2844-2844.	0.6	0
125	Differential Expression of Adhesion Molecules and Chemokine Receptors Confers Increased Migrative Capacity to ZAP-70-Positive Subclones in CLL Primary Cells,. Blood, 2011, 118, 3889-3889.	0.6	0
126	Salvage chemotherapy with alternating MINEâ€“ESHAP regimen in relapsed or refractory Hodgkinâ€™s lymphoma followed by autologous stem-cell transplantation. Annals of Oncology, 2010, 21, 1211-1216.	0.6	15

#	ARTICLE	IF	CITATIONS
127	The IV International Chronic Lymphocytic Leukemia Young Investigators' Meeting. <i>Leukemia and Lymphoma</i> , 2010, 51, 1369-1370.	0.6	0
128	Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. <i>Haematologica</i> , 2010, 95, 1526-1533.	1.7	158
129	Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 214-219.	0.8	27
130	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. <i>Leukemia and Lymphoma</i> , 2010, 51, 1225-1232.	0.6	36
131	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. <i>Cancer Research</i> , 2010, 70, 1408-1418.	0.4	429
132	Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study). <i>Blood</i> , 2010, 116, 1376-1376.	0.6	1
133	Rituximab Plus Gemcitabine and Oxaliplatin as Salvage Therapy In Patients with Relapsed/Refractory Mantle-Cell Lymphoma.. <i>Blood</i> , 2010, 116, 2825-2825.	0.6	2
134	Immune Status In Patients with Chronic Lymphocytic Leukemia and Sustained Complete Remission: A Multiparametric Analysis. <i>Blood</i> , 2010, 116, 1389-1389.	0.6	0
135	Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 4134-4134.	0.6	0
136	ZAP-70 Enhances BCR Signaling and Migration of Malignant B Lymphocytes towards CCL21 Via Induction of CCR7 Expression. <i>Blood</i> , 2010, 116, 3591-3591.	0.6	0
137	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4578-4584.	0.8	116
138	Gene expression profiling in chronic lymphocytic leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 211-222.	0.7	22
139	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Cl�nic of Barcelona experience. <i>Blood</i> , 2009, 114, 2044-2050.	0.6	132
140	Chronic Lymphocytic Leukemia Apoptotic Cell Death Induced by Glucocorticoids Is Mediated by BIM and GILZ and Can Be Predicted by FKBP5 Basal Expression Levels.. <i>Blood</i> , 2009, 114, 1236-1236.	0.6	6
141	The Prognostic Significance of Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009, 114, 2361-2361.	0.6	0
142	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2008, 68, 10178-10186.	0.4	67
143	Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. <i>Journal of Clinical Oncology</i> , 2008, 26, 4966-4972.	0.8	101
144	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161.	3.2	117

#	ARTICLE	IF	CITATIONS
145	Central nervous system involvement in mantle cell lymphoma. <i>Annals of Oncology</i> , 2008, 19, 135-141.	0.6	89
146	Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment. <i>Haematologica</i> , 2008, 93, 75-82.	1.7	22
147	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 132-136.	1.7	17
148	Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience. <i>Blood</i> , 2008, 112, 48-48.	0.6	1
149	No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 3615-3615.	0.6	5
150	Abdominal Computed Tomography Predicts Progression in Patients With Rai Stage 0 Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 1576-1580.	0.8	54
151	Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. <i>Blood</i> , 2007, 109, 259-270.	0.6	454
152	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	0.6	226
153	Leukemic involvement is a common feature in mantle cell lymphoma. <i>Cancer</i> , 2007, 109, 2473-2480.	2.0	82
154	Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 1141-1141.	0.6	2
155	SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. <i>Blood</i> , 2007, 110, 1585-1585.	0.6	0
156	Chronic Lymphocytic Leukemia (CLL): A Comparative Analysis of Protein Expression Profiles in Peripheral Blood Cells at Diagnosis and upon Disease Progression.. <i>Blood</i> , 2007, 110, 1129-1129.	0.6	0
157	Preliminary Results of the Combination Rituximab, Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) Followed by Rituximab Maintenance in Previously Untreated Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2007, 110, 626-626.	0.6	0
158	How I treat refractory CLL. <i>Blood</i> , 2006, 107, 1276-1283.	0.6	85
159	The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. <i>Annals of Oncology</i> , 2006, 17, 1539-1545.	0.6	107
160	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2006, 107, 4563-4569.	0.6	130
161	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. <i>European Journal of Haematology</i> , 2006, 76, 58-63.	1.1	36
162	Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 214-217.	0.7	26

#	ARTICLE	IF	CITATIONS
163	ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 726-734.	3.2	50
164	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3754-3761.	3.2	31
165	Over 20% of Patients with Chronic Lymphocytic Leukemia Carry Stereotyped Receptors: Pathogenetic Implications and Clinical Correlations.. <i>Blood</i> , 2006, 108, 26-26.	0.6	1
166	FMNL-1 (Formin-Like 1) Gene in Chronic Lymphocytic Leukemia (CLL) Is Overexpressed in Young Patients with Adverse Prognostic Factors and Poor Outcome.. <i>Blood</i> , 2006, 108, 2775-2775.	0.6	1
167	Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.. <i>Blood</i> , 2006, 108, 2835-2835.	0.6	3
168	ZAP-70 Expression and Stem Cell Transplantation Results in Patients with CLL.. <i>Blood</i> , 2006, 108, 3670-3670.	0.6	0
169	Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. <i>Blood</i> , 2006, 108, 2456-2456.	0.6	0
170	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. <i>Journal of Pathology</i> , 2005, 205, 507-513.	2.1	73
171	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. <i>Cancer Research</i> , 2005, 65, 2199-2206.	0.4	93
172	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. <i>Journal of Clinical Oncology</i> , 2005, 23, 2797-2804.	0.8	253
173	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3433-3438.	0.8	137
174	Expression of Specialized Error-Prone DNA Polymerases in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 2941-2941.	0.6	0
175	High Expression of Human Leukocyte Formin Protein in T Non-Hodgkinâ€™s Lymphomas and in CD19â€™ Cell Population of Normal Tonsils.. <i>Blood</i> , 2005, 106, 4662-4662.	0.6	0
176	Dexamethasone Induces Apoptosis â€œEx Vivoâ€™ in Chronic Lymphocytic Leukemia Cells with Either Unmutated IgVH Genes or High ZAP-70 Expression.. <i>Blood</i> , 2005, 106, 2945-2945.	0.6	0
177	Cytosolic Histone H1.2 Releasing under Different Apoptotic Stimuli in Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 2108-2108.	0.6	0
178	Clinical Significance of Minimal Residual Disease (MRD), as Assessed by Different Techniques, after Stem Cell Transplantation (SCT) for Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2005, 106, 1818-1818.	0.6	15
179	Improving treatment approach in patients with chronic lymphocytic leukemia. <i>Psychophysiology</i> , 2005, 4, 243-4.	1.1	0
180	Aminoglycoside-associated Severe Renal Failure in Patients with Multiple Myeloma Treated with Thalidomide. <i>Leukemia and Lymphoma</i> , 2004, 45, 1711-1712.	0.6	20

#	ARTICLE	IF	CITATIONS
181	Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. <i>Annals of Oncology</i> , 2004, 15, 1484-1489.	0.6	66
182	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. <i>Oncogene</i> , 2004, 23, 8941-8949.	2.6	23
183	Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. <i>American Journal of Pathology</i> , 2004, 164, 501-510.	1.9	92
184	Clinical Characteristics and Outcome of a Large Series of Patients with Chronic Lymphocytic Leukemia (CLL) According to ZAP-70 Expression.. <i>Blood</i> , 2004, 104, 14-14.	0.6	4
185	Prognostic Indicators of Chronic Lymphocytic Leukemia. , 2004, , 201-215.		1
186	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. <i>Blood</i> , 2004, 104, 697-697.	0.6	0
187	Quantitative PCR Predicts Early Relapse in Patients with Chronic Lymphocytic Leukemia (CLL) Submitted to Autologous Stem Cell Transplantation. The Case for Early Clinical Intervention.. <i>Blood</i> , 2004, 104, 2255-2255.	0.6	0
188	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. <i>Cancer Cell</i> , 2003, 3, 185-197.	7.7	848
189	Malignant transformation in IgM monoclonal gammopathy of undetermined significance. <i>Seminars in Oncology</i> , 2003, 30, 178-181.	0.8	17
190	ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2003, 348, 1764-1775.	13.9	1,194
191	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 71-76.	0.6	37
192	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003, 101, 78-84.	0.6	356
193	ZAP-70 in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2003, 349, 506-507.	13.9	5
194	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. <i>Annals of Oncology</i> , 2002, 13, 523-530.	0.6	42
195	ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. <i>Blood</i> , 2002, 99, 238-244.	0.6	151
196	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 1810-1816.	0.6	108
197	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). <i>American Journal of Pathology</i> , 2002, 161, 957-968.	1.9	86
198	Refining prognostic factors in chronic lymphocytic leukemia. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 335-349.	0.1	9

#	ARTICLE	IF	CITATIONS
199	True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. British Journal of Haematology, 2002, 116, 875-886.	1.2	14
200	Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2002, 117, 387-389.	1.2	7
201	Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. British Journal of Haematology, 2002, 119, 484-487.	1.2	10
202	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 119, 976-984.	1.2	163
203	Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. Leukemia, 2002, 16, 1454-1459.	3.3	38
204	Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood, 2001, 97, 2098-2104.	0.6	181
205	Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. Journal of Cutaneous Pathology, 2001, 28, 256-264.	0.7	32
206	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562.	2.0	22
207	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
208	Expression of Beta-Integrin Adhesion Molecules in Non-Hodgkin's Lymphoma: Correlation With Clinical and Evolutive Features. Journal of Clinical Oncology, 1999, 17, 1869-1869.	0.8	35
209	Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma. Cancer Genetics and Cytogenetics, 1999, 111, 92-98.	1.0	31
210	Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293.		44
211	Mantle cell lymphoma. , 1998, 82, 567-575.		302
212	Renal Failure in Multiple Myeloma. Archives of Internal Medicine, 1998, 158, 1889.	4.3	328
213	Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 1998, 9, 849-855.	0.6	264
214	Residual Splenic Function After Laparoscopic Splenectomy. Archives of Surgery, 1998, 133, 56-60.	2.3	78
215	Pyoderma Gangrenosum Triggered by $\hat{I}\pm 2b$ -Interferon in a Patient with Chronic Granulocytic Leukemia. Leukemia and Lymphoma, 1998, 30, 199-202.	0.6	41
216	Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: A report of 12 patients from a single institution. Annals of Oncology, 1998, 9, 167-172.	0.6	21

#	ARTICLE	IF	CITATIONS
217	Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatment. <i>European Journal of Haematology</i> , 1998, 61, 59-64.	1.1	11
218	Bone marrow assessment in B-cell chronic lymphocytic leukaemia: aspirate or biopsy? A comparative study in 258 patients. <i>British Journal of Haematology</i> , 1996, 93, 111-116.	1.2	35
219	An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. <i>European Journal of Haematology</i> , 1996, 57, 286-291.	1.1	24
220	Increased expression of the PRAD1/CCND1 gene in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1995, 91, 1025-1030.	1.2	97
221	Low-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single Institution. <i>Leukemia and Lymphoma</i> , 1994, 15, 159-165.	0.6	16
222	Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. <i>Cancer</i> , 1994, 73, 2913-2921.	2.0	65
223	Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. <i>British Journal of Haematology</i> , 1994, 88, 117-121.	1.2	56
224	Polycythaemia Vera Following Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1992, 8, 501-502.	0.6	4
225	Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: Response to treatment and factors influencing outcome. <i>Hematological Oncology</i> , 1992, 10, 301-309.	0.8	7